Get started
Author

Saloni Haldule

Observed name: S. Haldule
ORCID: 0000-0002-9002-0202
Observed ORCID: 0000-0002-9002-0202
OpenAlex ID: A5048720273
Post-publication promotion in rheumatology: a survey focusing on social media
2020 · Saloni Haldule, Samira Davalbhakta, et al. · Rheumatology International · 31
Psoriasiform rashes as the first manifestation of anti-MDA5 associated myositis
2020 · Upendra Rathore, Saloni Haldule, et al. · Lara D. Veeken · 14
A systematic review and meta-analysis of mycobacterial infections in patients with idiopathic inflammatory myopathies
2022 · Saloni Haldule, Moumita Chatterjee, et al. · Lara D. Veeken · 10
Consensus nomenclature and abbreviation for anti-synthetase syndrome: an IMACS project
2025 · Anushka Aggarwal, Tanya Chandra, et al. · Lara D. Veeken · 7
Quantitative radiomic analysis of computed tomography scans using machine and deep learning techniques accurately predicts histological subtypes of non-small cell lung cancer: A retrospective analysis
2025 · Suhrud Panchawagh, Arita Halder, et al. · European Journal of Surgical Oncology · 5
Heterogeneity in nomenclature and abbreviation usage for anti-synthetase syndrome: a scoping review
2024 · Anushka Aggarwal, Tanya Chandra, et al. · Rheumatology International · 1
MM-1205: Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma: From Surrogate Endpoint Validation to the Unanswered Question of Maintenance-Free Remission
2026 · Ashish Sharma, Sukhmani Sidhu, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-1183: Disparities in ASCT and CAR-T Access in Multiple Myeloma: Evidence From Real-World Studies in the Era of Novel Therapies
2026 · Ashish Sharma, Saloni Haldule, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-1189: Early Intervention vs Observation in High-Risk Smoldering Multiple Myeloma: Pooled Evidence From Randomized Trials and Real-World Cohorts
2026 · Ashish Sharma, Sukhmani Sidhu, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-1174: Infectious Morbidity With Bispecific T-Cell Engager Antibody Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Synthesis Revealing a Preventable Survival Gap
2026 · Ashish Sharma, Saloni Haldule, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-1174: Infectious Morbidity With Bispecific T-Cell Engager Antibody Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Synthesis Revealing a Preventable Survival Gap
2026 · Ashish Sharma, Saloni Haldule, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-1205: Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma: From Surrogate Endpoint Validation to the Unanswered Question of Maintenance-Free Remission
2026 · Ashish Sharma, Sukhmani Sidhu, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-1183: Disparities in ASCT and CAR-T Access in Multiple Myeloma: Evidence From Real-World Studies in the Era of Novel Therapies
2026 · Ashish Sharma, Saloni Haldule, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-1189: Early Intervention vs Observation in High-Risk Smoldering Multiple Myeloma: Pooled Evidence From Randomized Trials and Real-World Cohorts
2026 · Ashish Sharma, Sukhmani Sidhu, et al. · Clinical Lymphoma Myeloma & Leukemia
Fecal Immunochemical Test and Multitarget Stool DNA Testing for Colorectal Cancer Screening in Real-World Practice: A Literature Review
2026 · Ashish Sharma, Angad Tiwari, et al. · Journal of Clinical Medicine
PDF
Liquid biopsy at the finish line: End-of-treatment ctDNA predicts relapse and survival in diffuse large B-cell lymphoma.
2026 · Ashish Sharma, Harendra Kumar, et al. · Journal of Clinical Oncology
National trends and racial disparities in diffuse large B-cell lymphoma mortality in the United States, 1999–2023.
2026 · Harendra Kumar, Ashish Sharma, et al. · Journal of Clinical Oncology
ctDNA versus PET/CT at end of treatment in large B-cell lymphoma: A diagnostic accuracy meta-analysis.
2026 · Ashish Sharma, Harendra Kumar, et al. · Journal of Clinical Oncology
Neurocognitive outcomes after proton versus photon radiotherapy in pediatric CNS tumors: Systematic review and meta-analysis.
2026 · Saloni Haldule, Harendra Kumar, et al. · Journal of Clinical Oncology
Pharmacologic prevention of radiotherapy-induced nausea and vomiting: Network meta-analysis including olanzapine-based regimens.
2026 · Saloni Haldule, Ashish Sharma, et al. · Journal of Clinical Oncology
Nomenclature and abbreviation heterogeneity in immune-mediated necrotizing myopathy: A call for standardization
2026 · Maha Almackenzie, Niladri Bhowmick, et al. · Seminars in Arthritis and Rheumatism
Pos1026 Consensus Nomenclature and Abbreviation for Anti-synthetase Syndrome: Results From an Imacs Project
2025 · A. Aggarwal, T. Chandra, et al. · Annals of the Rheumatic Diseases
Myositis India: Early lessons from a patient support group in a resource‐limited setting
2024 · Anushka Aggarwal, Narendra Kumar Bagri, et al. · International Journal of Rheumatic Diseases
PDF
Ab0259 Anti Synthetase Syndrome: What’s in a Name?
2024 · A. Aggarwal, T. Chandra, et al. · Annals of the Rheumatic Diseases
Works count: 24
Citation count: 68
H-index: 5
I10-index: 3
Year
Topic
Type